Featured Content

The risks pharmaceutical companies face from natural and man-made disasters are increasing in both frequency and magnitude.

To ensure there is minimal interruption to the production of delivery of patient treatments in the wake of a disaster, supply chain leaders must implement a business continuity plan.

However, many companies are unprepared to protect their critical business functions and products in a complex supply network.

In this report, we shed light on the process of building a resilient supply chain, showing you how to:

• Understand the full scope of risks facing the pharmaceutical supply chain
• Protect and reinforce critical business processes and functions
• Ensure on-the-ground operational engagement
• Encourage a risk mitigation mindset across teams and partners
• Respond to a crisis situation effectively and learn from the process

Download your copy of this report to start building resiliency in your supply chain and secure your products from disaster.

The last mile presents unique challenges for maintaining drug quality and integrity, both in terms of inaccurate planning and a lack of integration between internal systems. In this article, with insights from Henry Moran Chief Operating Officer, ASC Associates Ltd, we explore:

• Who is responsible for the last mile?
• How can you mitigate the two most common causes of disruption in the last mile?
• How will Internet of Things (IoT)  shake things up in the last mile?

Multiple factors affect the decision to choose a particular mode of transport for pharmaceuticals. On the back of feedback received on the topic of air freight vs sea freight, Pharma IQ interviewed two industry experts about their thoughts on the continuing importance of air freight in the transportation of temperature controlled pharmaceuticals.

Approximately one-third of the medicines manufactured in Europe and the United States are now being tested and labeled for storage at controlled room temperature (CRT), mostly in the range of 15°C to 25°C and the proportion is increasing.

Pharma IQ sat down with Steve Winyard, Portfolio Strategy Manager Life Sciences at Inmark to discuss best practices for CRT transportation, an area which is facing increasing global regulatory scrutiny.